Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc. - SUPN
Kahn Swick & Foti, LLC announced it is investigating whether the price and process of Supernus Pharmaceuticals' proposed all-stock sale to Indivior adequately value the target. Supernus shareholders would receive 1.5401 Indivior shares per Supernus share under the proposed terms.
Key figures
- Exchange ratio
- 1.5401 Indivior shares per Supernus share
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.